Latest News and Press Releases

NEW HAVEN, Conn., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and...

NEW HAVEN, Conn., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and...

NEW HAVEN, Conn., Feb. 11, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and...

- ACH-5228, with improved potency and half-life, increases alternative pathway inhibition -- Achillion planning Investigational New Drug (IND) submission in fourth quarter of 2019 - NEW HAVEN, Conn.,...

NEW HAVEN, Conn., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and...

ACH-4471, First Generation Oral factor D Inhibitor- Proof of Concept Validated in both PNH as Monotherapy and in Combination w/C5 Inhibitor - Proof of Mechanism Validated in C3G, End of Phase 2...

NEW HAVEN, Conn., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company focused on advancing its orally administered factor D...

- Completed enrollment of Phase 2 clinical trial of ACH-4471 in PNH as monotherapy -- Interim data and strategic update planned for December 17, 2018 –- September 30, 2018 cash & securities...

NEW HAVEN, Conn., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) announced today that Joseph Truitt, President and Chief Executive Officer of Achillion, will...

NEW HAVEN, Conn., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) today announced the appointment of Paul Firuta to the position of Executive Vice President and...